Resources
73 Results (showing 51 - 60)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/21/2023 (updated 3/28/2024)
Disparities in access to naloxone exist and organizations are working to remove some of these barriers by utilizing innovative methods such as vending machines to distribute the overdose medication. This provides life-saving medication in an accessible way to everyone, although laws vary state to state on the distribution of these tools. More information on naloxone vending machines can be found in these resources by the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) and The Network for Public Health Law.
Posted 3/14/2023 (updated 3/27/2024)
Contingency management has empirical support but limited implementation. This report provides an overview of contingency management, barriers of implementation, and recommendation on how to overcome the challenges of implementation. Evidence-based treatment for people with stimulant use disorder is important as the U.S. has been experiencing an overdose crisis resulting in overdose deaths.
Posted 2/28/2023 (updated 3/27/2024)
This study's objective was to develop and validate a survey tool to assess emergency department physician attitudes, clinical practice, and willingness to perform opiate harm reduction interventions. After surveying physicians, most showed they were willing to provide necessary interventions, while few do perform them. Although there was an increased willingness to perform the interventions, a disparity remains.
Posted 6/7/2022 (updated 3/27/2024)
This session had three presenters who covered contingency management, prevention of stimulant use for children, and peer support.
Posted 6/7/2022 (updated 3/27/2024)
This presentation featured an overview of epidemiology of stimulant use, describe toxicities of stimulant use, and identify interventions to address stimulant use.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 10/3/2022 (updated 3/27/2024)
Nitazenes are a novel group of powerful illicit synthetic opioids derived from 2-benzylbenzimidazole that have been linked to overdose deaths in several states. Nitazenes were created as a potential pain reliever medication nearly 60 years ago but have never been approved for use in the United States. Laboratory test results indicate that the potency of certain nitazene analogs (e.g., isotonitazene, protonitazene, and etonitazene) greatly exceeds that of fentanyl, whereas the potency of the analog metonitazene is similar to fentanyl.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.